EGFR and breast carcinoma: Moreover, genetically engineered CAR-T cells have been developed targeting commonly expressed breast cancer antigens such as HER2 (Szoor et al., 2020), EGFR (Liu et al., 2019), EpCAM (Osta et al., 2004), AXL (Zhao et al., 2020a) and c-MET (Tchou et al., 2017).